Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GR1802 in Chronic Spontaneous Urticaria (Phase II)
CTR20230559Phase 2Completed
- Sponsor
- Zhixiang Jintai
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic idiopathic urticaria (CIU) comparing GR1802 with Placebo (2 arms). Primary endpoint: Change from baseline in Urticaria Activity Score over 7 days (UAS7) at Week 16. Started Mar 2023; status: completed.
02
Drugs
telikibart
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on CTR20230559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230559.